ScottESmithMDPhD, FACP
Hematology • Maywood, ILHematologic Oncology
Professor of Medicine Section Chief, Hematology Director, Bone Marrow Transplant Loyola University Chicago Stritch School of Medicine
Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2160 S First Ave
Cancer Center
Maywood, IL 60153Phone+1 708-327-3142Fax+1 708-327-3219
Summary
- Dr. Scott Smith is an oncologist in Maywood, IL and is affiliated with multiple hospitals in the area, including Loyola University Medical Center and Edward Hines, Jr. Veterans Affairs Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice 21 years. He is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hematopoietic stem cell transplantation.
Clinical Expertise
- Hematopoietic stem cell transplantation, Oropharyngeal lymphoma, Cold autoimmune hemolytic anemia, Hairy cell leukemia, Gastric lymphoma, Hematologic oncology, Hodgkin's lymphoma
Education & Training
Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003- Loyola University Medical CenterResidency, Internal Medicine, 1996 - 2000
Wayne State University School of MedicineClass of 1996
Certifications & Licensure
IL State Medical License 1998 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma Start of enrollment: 2005 Jul 01
- Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Jul 01
- Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2009 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 123 citationsA retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.Andrew M. Evens, Irene Helenowski, Erika Ramsdale, Chadi Nabhan, Reem Karmali
Blood. 2012-01-19 - 284 citationsFive-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert T. Chen, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt
Blood. 2016-09-22 - 23 citationsPembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investiga...Locke J Bryan, Carla Casulo, Pamela B Allen, Scott E Smith, Hatice Savas
JAMA Oncology. 2023-05-01
Abstracts/Posters
- Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...Scott E. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Mu...Scott E. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Loyola Medicine Section Chief of Hematology Available to Discuss Liam Hendriks' Cancer DiagnosisJanuary 9th, 2023
Treating Uninsured Patients Is Wreaking Havoc on Cook County FinancesMarch 12th, 2020
New Leukemia Drug Is More Effective and Easier to UseJanuary 11th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
